What the MRI looks like after a ChondroFiller injection

At a follow-up appointment, the question on most patients' minds is simple: does the MRI show anything actually happening? The answer, in knees that respond well to the ChondroFiller injection, is a measurable and progressive change tracked through a validated scoring system called MOCART 2.0.

MOCART scores run from 0 to 100 and assess five structural domains on MRI: volumetric defect fill, peripheral integration with native cartilage, surface congruence, repair tissue signal intensity, and subchondral bony changes. A score above 80 indicates that more than 80% of the defect has been filled with repair tissue that is integrating well with the surrounding cartilage — structural confirmation of scaffold incorporation, not merely space-filling.

The documented maturation curve across European multi-site PMCF data (Jerosch et al.) shows a mean MOCART of 65.3 at four weeks, rising to 81.6 at twelve months, and remaining at 81.6–84.3 at three years. Published one-year values across multiple cohorts — including the Simeonov 2024 series (n=17, mean age 31) — consistently cluster in the 70–87 range.

This progression reflects the underlying biology. A 2025 ex vivo osteochondral model showed a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, confirming that the injectable collagen scaffold actively recruits the patient's own progenitor cells rather than simply occupying space. MRI changes therefore accumulate over months as those recruited cells mature.

Scores above 60 are associated with clinically meaningful pain relief. The trajectory from a score in the mid-60s at four weeks to above 80 at twelve months represents the expected pattern in a well-selected candidate — and it is normal for symptom improvement to outpace what the MRI shows in the early months.

Bone marrow oedema on knee MRI — what the signal means

Bone marrow oedema — occasionally labelled bone marrow lesion (BML) in radiology reports, a terminology shift that dates to studies showing inflammatory responses are the primary driver rather than simple fluid influx — appears on fat-suppressed MRI sequences as a bright patch in the trabecular bone beneath a cartilage defect. It is a subchondral signal, not a cartilage signal: the bone is responding to elevated mechanical stress at the point where the cartilage surface can no longer distribute load evenly.

This distinction matters for interpreting a post-injection MRI. After a ChondroFiller injection, the collagen scaffold fills and integrates with the defect over weeks and months, progressively restoring the surface through which compressive load is transmitted. As subchondral stress reduces, the BME signal typically fades — in most reversible cases, resolution occurs within a 3–6 month window, managed with rest and appropriate anti-inflammatory support where needed.

The link to objective MRI measurement is direct: MOCART 2.0 includes a dedicated bony-changes domain that grades subchondral signals — including BME-type changes — beneath the repair site. As MOCART scores in ChondroFiller-treated knees rise from a mean of 65.3 at four weeks toward the 80-plus range at twelve months, improving subchondral status is part of what those rising scores reflect. No published dataset reports BME resolution as a standalone endpoint specifically for ChondroFiller injection; the bony-changes domain within MOCART is how subchondral response is captured in the available evidence, and its upward trajectory over twelve months is the clearest proxy for improving bone stress beneath the repair.

How MOCART 2.0 and MOAKS score the repair — and what those numbers mean

Two validated MRI tools are relevant to follow-up after a ChondroFiller injection, and they serve different purposes.

MOCART concentrates entirely on the treatment site — its domains assess only the focal repair zone. MOAKS (MRI Osteoarthritis Knee Score) takes a wider view: a validated whole-joint scoring system, it grades bone marrow lesion severity, cartilage quality, and joint space changes across the entire knee. In straightforward ChondroFiller follow-up, MOCART remains the primary structural metric; MOAKS becomes the more relevant tool when the wider joint is also being monitored — for example, where early-to-moderate osteoarthritic change was present at baseline and the clinician wants a complete joint-health picture alongside the focal repair.

A follow-up MRI report will typically read as a narrative, not a single number. Patients can expect commentary on defect fill, integration margins, signal homogeneity of the repair tissue, and subchondral status. If a MOAKS-style grading appears — phrases such as 'BML grade 2' — that reflects the same subchondral stress signal discussed above, scored across the joint map rather than beneath the focal repair alone.

At Lincolnshire Knee, onMRI™ adds quantitative AI-assisted cartilage segmentation and T2 mapping to this structural picture — tissue-quality data that a standard radiologist report does not routinely include.

Functional improvement alongside the MRI findings

The short answer to the question patients most often raise — 'if my MRI at four weeks still shows incomplete fill, does that mean the injection has failed?' — is no. The functional evidence makes that clear.

In the Jerosch PMCF cohort, mean IKDC scores rose from approximately 48 at baseline to 80 at 36 months, a gain of 32.4 points. That figure is nearly double the 16.7-point minimal clinically important difference (MCID) for the IKDC — the validated threshold below which a score change is not considered meaningful to the patient. Simeonov's 2024 cohort (n=17, mean age 31) recorded statistically significant IKDC improvements at 3, 6, and 12 months (p<0.05), replicating the trajectory in a younger, more active population.

Structural and functional signals do not always synchronise. Some patients notice a meaningful reduction in pain and improved activity tolerance well before MRI confirms mature tissue fill; in others, solid structural appearance on imaging coexists with residual symptoms that resolve later. Neither pattern indicates a problem with the scaffold — they reflect the biological reality that cell recruitment, scaffold integration, and symptom resolution operate on overlapping but distinct timelines.

This dissociation is why using MOCART and IKDC in parallel gives a more complete picture than either measure alone. A MOCART reading taken four weeks after injection captures early-stage incorporation; it describes where the repair is at that point, not where it will be at twelve months.

Why MRI can underestimate defect size — and what that means for candidacy

Sizing a cartilage defect accurately on MRI is harder than it looks — and the discrepancy has direct consequences for treatment planning.

Gomoll (PMC4297136; n=38 knees) found that the true post-debridement defect area was on average 65% larger than the MRI estimate, with 85% of defects exceeding their predicted size. The discrepancy ranged from 47% to 377% depending on lesion location. In practical terms: a defect appearing to measure 1.5 cm² on standard imaging could realistically be closer to 2.5 cm² once properly assessed.

This matters directly for ChondroFiller candidacy. The treatment's CE-marked evidence base centres on focal defects typically up to 3 cm², extendable to 6 cm² per the clinical evaluation report. A patient who appears eligible on pre-procedure MRI may, on specialist assessment, prove to have a defect that sits outside the optimal treatment window — or one that warrants a different repair strategy altogether.

None of this undermines MRI as an assessment tool; it remains the essential first step in cartilage evaluation. The clinical implication is that MRI review should form part of a structured assessment process, not stand alone as its conclusion. At Lincolnshire Knee, pre-treatment planning may incorporate onMRI™ AI-assisted lesion mapping to help characterise defect boundaries more precisely — an additional sizing input before any treatment decision is reached.

UK patient pathway — who suits ChondroFiller injection and what follow-up involves

Not every knee with cartilage damage suits a ChondroFiller injection — understanding the candidacy criteria is the first practical step.

The target profile is a focal, contained cartilage defect at Grade III or IV severity in a joint rated Kellgren-Lawrence I–III. Advanced bone-on-bone osteoarthritis (KL grade IV) falls outside scope, as the surrounding joint must be sufficiently intact to support scaffold integration and cell recruitment. Published evidence centres on defects typically up to 3 cm².

In the UK the treatment is self-funded: CE-marked but not NHS-commissioned, and not covered by Bupa or AXA. Cost runs from £3,000 (single box, including consultation and ultrasound-guided injection) to £8,000 for three boxes.

The published safety record across more than 19,000 global cases shows a serious complication rate of approximately 0.06%, with 70–85% of patients reporting meaningful relief at three to five years. A reoperation rate of 3–8% contrasts with rates of up to 41% reported for microfracture — though that figure derives from observational data rather than a head-to-head trial. The evidence base rests on prospective cohort and PMCF studies rather than large RCTs, a point worth stating plainly when patients are weighing this against surgical alternatives.

Structured follow-up typically includes a clinical review at around six weeks and an MRI assessment at twelve months, evaluated against the MOCART maturation trajectory described in earlier sections — with earlier imaging at four weeks where clinically indicated.

Lincolnshire Knee (MSK Doctors group) accepts patients without GP referral and without NHS-style waiting lists. The ChondroFiller injection pathway is available at the Sleaford (NG34) and Grantham (NG31) sites.